Insider Transactions in Q1 2025 at Biogen Inc. (BIIB)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2025
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
245
-2.97%
|
$34,790
$142.54 P/Share
|
|
Feb 10
2025
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
834
+9.17%
|
-
|
|
Feb 10
2025
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,371
-5.33%
|
$194,682
$142.54 P/Share
|
|
Feb 10
2025
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,257
+11.24%
|
-
|
|
Feb 10
2025
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
670
-4.55%
|
$95,140
$142.54 P/Share
|
|
Feb 10
2025
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,272
+13.37%
|
-
|
|
Feb 10
2025
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-3.79%
|
$50,694
$142.54 P/Share
|
|
Feb 10
2025
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,212
+11.4%
|
-
|
|
Feb 10
2025
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
445
-4.95%
|
$63,190
$142.54 P/Share
|
|
Feb 10
2025
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,515
+14.41%
|
-
|
|
Feb 10
2025
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
807
-2.18%
|
$114,594
$142.54 P/Share
|
|
Feb 10
2025
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,575
+6.49%
|
-
|
|
Feb 10
2025
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-3.48%
|
$90,028
$142.54 P/Share
|
|
Feb 10
2025
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,159
+10.59%
|
-
|
|
Feb 07
2025
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
3,844
+20.34%
|
-
|
|
Feb 07
2025
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,165
-8.42%
|
$164,265
$141.35 P/Share
|
|
Feb 07
2025
|
Christopher Viehbacher President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,201
-20.0%
|
$451,341
$141.35 P/Share
|
|
Feb 07
2025
|
Christopher Viehbacher President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,008
+36.01%
|
-
|
|
Feb 07
2025
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,502
-3.35%
|
$211,782
$141.35 P/Share
|
|
Feb 07
2025
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,551
+9.21%
|
-
|
|
Feb 07
2025
|
Adam Keeney Head of Corporate Development |
SELL
Payment of exercise price or tax liability
|
Direct |
563
-22.86%
|
$79,383
$141.35 P/Share
|
|
Feb 07
2025
|
Adam Keeney Head of Corporate Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,801
+42.24%
|
-
|
|
Feb 07
2025
|
Jane Grogan Head of Research |
SELL
Payment of exercise price or tax liability
|
Direct |
443
-23.61%
|
$62,463
$141.35 P/Share
|
|
Feb 07
2025
|
Jane Grogan Head of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
1,385
+42.47%
|
-
|
|
Feb 07
2025
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-7.66%
|
$96,021
$141.35 P/Share
|
|
Feb 07
2025
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,216
+19.95%
|
-
|
|
Feb 07
2025
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
1,223
-4.95%
|
$172,443
$141.35 P/Share
|
|
Feb 07
2025
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
4,042
+14.06%
|
-
|
|
Feb 07
2025
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
476
-3.2%
|
$67,116
$141.35 P/Share
|
|
Feb 07
2025
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,491
+9.14%
|
-
|
|
Feb 07
2025
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,234
-1.79%
|
$173,994
$141.35 P/Share
|
|
Feb 07
2025
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,130
+5.66%
|
-
|
|
Feb 07
2025
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,040
-3.25%
|
$146,640
$141.35 P/Share
|
|
Feb 07
2025
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
3,436
+9.71%
|
-
|
|
Jan 31
2025
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
578
-7.97%
|
$82,654
$143.93 P/Share
|
|
Jan 31
2025
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,828
+20.13%
|
-
|